Exagen Diagnostics Launches Cutting-Edge Lupus Diagnostic
Avise SLE Fills a Gap in the Lupus Diagnostic Market Using CB-CAPs Technology
ALBUQUERQUE, N.M., Jan. 9, 2012 /PRNewswire/ -- Exagen Diagnostics, Inc., a specialty focused molecular diagnostics laboratory that discovers, develops and markets proprietary tests for rheumatologists and gastroenterologists, announced today the launch of Avise SLE, which aids in the diagnosis of lupus (Systemic Lupus Erythematosus).
Avise SLE is a 5-marker panel designed to Rule-In SLE and Rule-Out other rheumatic diseases to help establish the most accurate SLE diagnosis. Specifically, the panel includes testing of ANA, dsDNA, Avise MCV, EC4d and BC4d. The Avise SLE diagnostic differentiates itself by using cell-bound complements because of their increased performance over soluble complements which helps to accurately and consistently diagnose SLE.
Avise SLE is most impactful when ordered as a first step in patient treatment to help physicians with diagnosis by providing:
- Efficiency - 5 individual markers, 1 blood draw
- Confidence in Diagnosis - From a panel that rules-in SLE and rules-out other rheumatic diseases
- Increased Accuracy - Using CB-CAPs technology to achieve 78% sensitivity and 87% specificity for other diseases/97% specificity for normal/healthy patients
- Convenience - We provide kits, pay shipping costs and return test results in 7 business days
"Exagen is excited to offer a breakthrough diagnostic that uses CB-CAPs technology to help accurately determine if a patient has lupus," said Ron Rocca, President and CEO. "Because diagnosing lupus is so difficult and early diagnosis is critical in avoiding major organ damage, developing an accurate diagnostic to fill the unmet need for rheumatologists was a top priority. We have been able to do that with Avise SLE and are pleased to take part in helping physicians gain control over this serious disease."
Exagen Diagnostics, Inc. is a patient focused, discovery driven, CLIA registered, CAP certified laboratory with a growing menu of proprietary, internally developed tests focused in the areas of Rheumatology and Gastroenterology. Committed to Personalized Medicine, our tests are specifically designed to provide objective information to physicians and patients for more accurate, efficient diagnosis and better disease management. Using uniquely powerful Coperna® discovery technology, Exagen identifies and validates small sets of genomic markers which are used to create meaningful, easily interpreted diagnostic tests for clinical use. For more information, please visit www.Exagen.com or www.AviseTest.com.
SOURCE Exagen Diagnostics, Inc.
More by this Source
Exagen Diagnostics, Inc. and Capital Royalty Close Financing Transaction
Nov 04, 2013, 09:00 ET
Exagen Diagnostics Appoints New Board Member
Oct 28, 2013, 09:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.